153 related articles for article (PubMed ID: 38652736)
1. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970-2016.
Orme S; McNally R; James PW; Davis J; Ayuk J; Higham C; Wass J;
Clin Endocrinol (Oxf); 2024 Jun; 100(6):558-564. PubMed ID: 38652736
[TBL] [Abstract][Full Text] [Related]
2. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.
Orme SM; McNally RJ; Cartwright RA; Belchetz PE
J Clin Endocrinol Metab; 1998 Aug; 83(8):2730-4. PubMed ID: 9709939
[TBL] [Abstract][Full Text] [Related]
3. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
4. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
5. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.
Lin E; Wexler TL; Nachtigall L; Tritos N; Swearingen B; Hemphill L; Loeffler J; Biller BM; Klibanski A; Miller KK
Clin Endocrinol (Oxf); 2012 Sep; 77(3):430-8. PubMed ID: 22315983
[TBL] [Abstract][Full Text] [Related]
6. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
[TBL] [Abstract][Full Text] [Related]
7. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
[TBL] [Abstract][Full Text] [Related]
9. The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study.
Varadhan L; Reulen RC; Brown M; Clayton RN
Pituitary; 2016 Jun; 19(3):251-61. PubMed ID: 26724807
[TBL] [Abstract][Full Text] [Related]
10. Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature.
Dal J; Leisner MZ; Hermansen K; Farkas DK; Bengtsen M; Kistorp C; Nielsen EH; Andersen M; Feldt-Rasmussen U; Dekkers OM; Sørensen HT; Jørgensen JOL
J Clin Endocrinol Metab; 2018 Jun; 103(6):2182-2188. PubMed ID: 29590449
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
12. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
[TBL] [Abstract][Full Text] [Related]
13. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
14. The critical parameters in GH excess.
Sheppard MC
J Endocrinol Invest; 2005; 28(5 Suppl):92-5. PubMed ID: 16114283
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study.
Xiao T; Jiao R; Yang S; Wang Y; Bai X; Zhou J; Li R; Wang L; Yang H; Yao Y; Deng K; Gong F; Pan H; Duan L; Zhu H
Endocrine; 2023 Nov; 82(2):368-378. PubMed ID: 37442901
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.
Wexler TL; Durst R; McCarty D; Picard MH; Gunnell L; Omer Z; Fazeli P; Miller KK; Klibanski A
Growth Horm IGF Res; 2010 Oct; 20(5):333-7. PubMed ID: 20598930
[TBL] [Abstract][Full Text] [Related]
17. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study.
Colao A; Grasso LFS; Di Cera M; Thompson-Leduc P; Cheng WY; Cheung HC; Duh MS; Neary MP; Pedroncelli AM; Maamari R; Pivonello R
J Endocrinol Invest; 2020 Apr; 43(4):529-538. PubMed ID: 31741320
[TBL] [Abstract][Full Text] [Related]
18. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.
Sherlock M; Reulen RC; Alonso AA; Ayuk J; Clayton RN; Sheppard MC; Hawkins MM; Bates AS; Stewart PM
J Clin Endocrinol Metab; 2009 Nov; 94(11):4216-23. PubMed ID: 19808848
[TBL] [Abstract][Full Text] [Related]
19. Excess mortality in acromegaly.
Holdaway IM
Horm Res; 2007; 68 Suppl 5():166-72. PubMed ID: 18174739
[TBL] [Abstract][Full Text] [Related]
20. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
